A review of mechanistic insight and application of pH-sensitive liposomes in drug delivery

Drug Delivery

Volumn 22, Issue 3, 2015, Pages 231-242

  Paliwal, Shivani Rai ^a   Paliwal, Rishi ^b   Vyas, Suresh P ^c  

^a GURU GHASIDAS UNIVERSITY   (India)

^b Department of Pharmaceutical Analysis and Quality Assurance   (India)

^c Department of Pharmaceutical Sciences   (India)

Author keywords

Chemotherapy; Drug gene delivery; Fusogenicity; Intracellular delivery; PH sensitive lipid

Indexed keywords

IMMUNOLIPOSOME; LIPOSOME; POLYMER; VACCINE; DNA; DRUG; DRUG CARRIER; LIPID;

ACIDIFICATION; AREA UNDER THE CURVE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GENE THERAPY; DRUG DELIVERY SYSTEM; ENDOCYTOSIS; HUMAN; INTERNALIZATION; LIPOSOMAL GENE DELIVERY SYSTEM; NONHUMAN; OXIDATION REDUCTION POTENTIAL; PH; PHAGOCYTOSIS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROTON TRANSPORT; REVIEW; TUMOR DIAGNOSIS; VACCINATION; CHEMISTRY; GENE TRANSFER; GENETICS; PROCEDURES; THERANOSTIC NANOMEDICINE;

DNA; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; GENE TRANSFER TECHNIQUES; HUMANS; HYDROGEN-ION CONCENTRATION; LIPIDS; LIPOSOMES; PHARMACEUTICAL PREPARATIONS; POLYMERS; THERANOSTIC NANOMEDICINE;

EID: 84930433440     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.3109/10717544.2014.882469     Document Type: Review

References (96)

1. Abra RM, Bankert RB, Chen F, et al. (2002). The next generation of liposome Delivery systems: recent experience with tumor-targeted, sterically stabilized immunoliposomes and active loading gradients. J Liposome Res 12:1-3
2. Andresen TL, Jensen SS, Jorgensen K. (2005). Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release. Prog Lipid Res 44:68-97
3. Andrews CD, Huh MS, Patton K, et al. (2012). Encapsulating immunostimulatory CpG oligonucleotiDes in listeriolysin O-liposomes promotes a Th1-type response and CTL activity. Mol Pharm 9: 1118-25
4. Araujo JG, Mota Ld, Leite EA, et al. (2011). Biodistribution and antitumoral effect of long-circulating and pH-sensitive liposomal cisplatin administered in Ehrlich tumor-bearing mice. Exp Biol Med (Maywood) 236:808-15
5. Bareford LM, Swaan PW. (2007). Endocytic mechanisms for targeted drug Delivery. Adv Drug Deliv Rev 59:748-58
6. Bertrand N, Simard P, Leroux JC. (2010). Serum-stable, longcirculating, pH-sensitive PEGylated liposomes. Methods Mol Biol 605:545-58
7. Chang JS, Choi MJ, Cheong HS, Kim K. (2001). Development of Th1-mediated CD8 effector T cells by vaccination with epitope peptiDes encapsulated in pH-sensitive liposomes. Vaccine 19:3608-14
8. Chang JS, Choi MJ, Kim TY, et al. (1999). Immunogenicity of synthetic HIV-1 V3 loop peptiDes by MPL adjuvanted pH-sensitive liposomes. Vaccine 17:1540-8
9. Chen D, Liu W, Shen Y, et al. (2011). Effects of a novel pH-sensitive liposome with cleavable esterase-catalyzed and pH-responsive double smart mPEG lipid Derivative on ABC phenomenon. Int J Nanomed 6: 2053-61
10. Chen H, Zhang H, Thor D, et al. (2012). Novel pH-sensitive cationic lipids with linear ortho ester linkers for gene Delivery. Eur J Med Chem 52:159-72
11. Chen Y, Sun J, Lu Y, et al. (2013). Complexes containing cationic and anionic pH-sensitive liposomes: comparative study of factors influencing plasmid DNA gene Delivery to tumors. Int J Nanomed 8:1573-93
12. Collins D. (1995). pH-sensitive liposomes as tools for cytoplasmic Delivery. In: Philippot JR, Schuber F, eds. Liposomes as tools in basic research and industry. Boca Raton: CRS Press, 201-14
13. Conner J, Huang L. (1986). pH-sensitive Immunoliposomes as an efficient and target-specific carrier for antitumor drugs. Cancer Res 46:3431-5
14. Connor J, Yatvin MB, Huang, L. (1984). pH-sensitive liposomes: acidinduced liposome fusion. Proc Natl Acad Sci USA 81:1715-18
15. De Barros ALB, Mota LDG, Soares DCF, et al. (2011). Tumor bombesin analog loaDed long-circulating and pH-sensitive liposomes as tool for tumor iDentification. Bioorg Med Chem Lett 21:7373-5
16. Di Marzio L, Marianecci C, Cinque B, et al. (2008). pH-sensitive nonphospholipid vesicle and macrophage-like cells: binding, uptake and endocytotic pathway. Biochim Biophys Acta 1778:2749-56
17. Dos Santos Giuberti C, De Oliveira Reis EC, Ribeiro Rocha TG, et al. (2011). Study of the pilot production process of long-circulating and pH-sensitive liposomes containing cisplatin. J Liposome Res. 21. 60-9
18. Drummond DC, Zignani M, Leroux J. (2000). Current status of pH-sensitive liposomes in drug Delivery. Prog Lipid Res 39:409-60
19. Ducat E, Deprez J, Gillet A, et al. (2011). Nuclear Delivery of a therapeutic peptiDe by long circulating pH-sensitive liposomes: benefits over classical vesicles. Int J Pharm 420:319-32
20. Duzgunes N, Straubinger RM, Baldwin PA, et al. (1985). Proton-induced fusion of oleic acid-phosphatidylethanolamine liposomes. Biochemistry 24:3091-8
21. Fattal E, Couvreur P, Dubernet C. (2004). Smart Delivery of antisense oligonucleotiDes by anionic pH-sensitive liposomes. Adv Drug Deliv Rev 56:931-46
22. Ferreira SM, Domingos GP, Ferreira Ddos S, et al. (2012). Technetium-99m-labeled ceftizoxime loaDed long-circulating and pH-sensitiveliposomes used to iDentify osteomyelitis. Bioorg Med Chem Lett 22: 4605-8
23. Gerasimov OV, Boomer JA, Qualls MM, Thompson DH. (1999). Cytosolic drug Delivery using pH-and light-sensitive liposomes. Adv Drug Deliv Rev 38:317-38
24. Guo W, Gosselin MA, Lee RJ. (2002). Characterization of novel dioleinbased LPDII vector for gene Delivery. J Control Rel 83:121-32
25. Hong MS, Lim SJ, Oh YK, Kim CK. (2002). pH-sensitive, serum-stable and long-circulating liposomes as a new drug Delivery system. J Pharm Pharmacol 54:51-8
26. Huang A, Tsao YS, Kennel SJ, Huang L. (1982). Characterization of antibody covalently coupled to liposomes. Biochim Biophys Acta 716: 140-50
27. Jiang T, Zhang Z, Zhang Y, et al. (2012). Dual functional liposomes based on pH-responsive cell-penetrating peptiDe and hyaluronic acid for tumor-targeted anticancer drug Delivery. Biomaterials 33: 9246-58
28. Junior AD, Mota LG, Nunan EA, et al. (2007). Tissue distribution evaluation of stealth pH-sensitive liposomal cisplatin versus free cisplatin in Ehrlich tumor-bearing mice. Life Sci 80:659-64
29. Kale AA, Torchilin VP. (2007). Smart drug carriers: PEGylated TATp-modified pH-sensitive liposomes. J Liposome Res 17:197-203
30. Karanth H, Murthy RS. (2007). pH-sensitive liposomes-principle and application in cancer therapy. J Pharm Pharmacol 59:469-83
31. Khalil IA, Hayashi Y, Mizuno R, Harashima H. (2011). Octaarginineand pH sensitive fusogenic peptiDe-modified nanoparticles for livergene Delivery. J Control Rel 156:374-80
32. Kim IY, Kang YS, Lee DS, et al. (2009). Antitumor activity of EGFR targeted pH-sensitive immunoliposomes encapsulating gemcitabine in A549 xenograft nuDe mice. J Control Rel 140:55-60
33. Kim MJ, Lee HJ, Lee IA, et al. (2008). Preparation of pH-sensitive, long-circulating and EGFR-targeted immunoliposomes. Arch Pharm Res 31:539-46
34. Kono K, Zenitani K, Takagishi T. (1994). Novel pH-sensitive liposomes: liposomes bearing a poly(ethylene glycol) Derivative with carboxyl groups. Biochim Biophys Acta 1193:1-9
35. Koren E, Apte A, Jani A, Torchilin VP. (2012). Multifunctional PEGylated 2C5-immunoliposomes containing pH-sensitive bonds and TAT peptiDe for enhanced tumor cell internalization and cytotoxicity. J Control Rel 160:264-73
36. Koynova R, Wang L, MacDonald RC. (2006). An intracellular lamellarenonlamellar phase transition rationalizes the superior performance of some cationic lipid transfection agents. Proc Natl Acad Sci USA 103:14373-8
37. Lai MZ, Duzgunes N, Szoka FC. (1985). Effects of replacement of the hydroxyl group of cholesterol and tocopherol on the thermotropic behavior of phospholipid membranes. Biochemistry 24: 1646-53
38. Lee KY, Chun E, Seong BL. (2002). Investigation of antigen Delivery route in vivo and immune-boosting effects mediated by pH-sensitive liposomes encapsulated with Kb-restricted CTL epitope. Biochem Biophys Res Commun 292:682-8
39. Leite EA, Giuberti Cdos S, Wainstein AJ, et al. (2009). Acute toxicity of long-circulating and pH-sensitive liposomes containing cisplatin in mice after intraperitoneal administration. Life Sci 84:641-9
40. Leroux J, Roux E, Le Garrec D, et al. (2001). N-IsopropylacrylamiDe copolymers for the preparation of pH-sensitive liposomes and polymeric micelles. J Control Rel 72:71-84
41. Leserman L, Machy P, Leonetti JP, et al. (1990). Targeted liposomes and intracellular Delivery of macromolecules. Prog Clin Biol Res 343: 95-102
42. Li P, Liu D, Miao L, et al. (2012). A pH-sensitive multifunctional gene carrier assembled via layer-by-layer technique for efficient gene Delivery. Int J Nanomed 7:925-39
43. Litzinger DC, Huang L. (1992). Phosphatidylethanolamine liposomes: drug Delivery, gene transfer and immunodiagnostic applications. Biochim Biophys Acta 1113:201-27
44. Lutwyche P, CorDeiro C, Wiseman DJ, et al. (1998). Intracellular Delivery and antibacterial activity of gentamicin encapsulated in pH-sensitive liposomes. Antimicrob Agents Chemother 42:2511-20
45. Mo R, Sun Q, Li N, Zhang C. (2013). Intracellular Delivery and antitumor effects of pH-sensitive liposomes based on zwitterionic oligopeptiDe lipids. Biomaterials 34:2773-86
46. Momekova D, Rangelov S, Lambov N. (2010). Long-circulating, pH-sensitive liposomes. Methods Mol Biol 605: 527-44
47. Moore NM, Barbour TR, Sakiyama-Elbert SE. (2008). Synthesis and characterization of four-arm poly(ethylene glycol)-based gene Delivery vehicles coupled to integrin and DNA-binding peptiDes. Mol Pharm 5:140-50
48. Nakamura K, Kuramoto Y, Mukai H, et al. (2009). Enhanced gene transfection in macrophages by histidine-conjugated mannosylated cationic liposomes. Biol Pharm Bull 32:1628-31
49. Nayar R, Schroit AJ. (1985). Generation of pH-sensitive liposomes: use of large unilamellar vesicles containing N-succinyldioleoylphosphatidylethanolamine. Biochemistry 24:5967-71
50. Paliwal SR, Paliwal R, Agrawal GP, Vyas SP. (2011). Liposomal nanomedicine for breast cancer therapy. Nanomedicine (London) 6: 1085-100
51. Paliwal SR, Paliwal R, Pal HC, et al. (2012). Estrogen-anchored pH-sensitive liposomes as nanomodule Designed for site-specific Delivery of doxorubicin in breast cancer therapy. Mol Pharm 9: 176-86
52. Paliwal SR, Paliwal R, Vyas SP. (2013). pH-sensitive liposome in drug Delivery. In: Alvarez-Lorenzo C, Concheiro A, eds. Smart materials for drug Delivery. Vol. 1. UK: Royal Society of Chemistry, 80-93
53. Pedroso De Lima MC, Simoes S, Pires P, et al. (2001). Cationic lipid-DNA complexes in gene Delivery: from biophysics to biological applications. Adv Drug Deliv Rev 47:277-94
54. Pichon C, Midoux P. (2013). Mannosylated and histidylated LPR technology for vaccination with tumor antigen mRNA. Methods Mol Biol 969:247-74
55. Rodrigues PC, Beyer U, Schumacher P, et al. (1999). Acidsensitive polyethylene glycol conjugates of doxorubicin: preparation, in vitro efficacy and intracellular distribution. Bioorg Med Chem 7: 2517-24
56. Rosa M, Penacho N, Simoes S, et al. (2008). DNA pre-conDensation with an amino acid-based cationic amphiphile. A viable approach for liposome-based gene Delivery. Mol Membr Biol 25:23-34
57. Roux E, Francis M, Winnik FM, Leroux JC. (2002a). Polymer based pH-sensitive carriers as a means to improve the cytoplasmic Delivery of drugs. Int J Pharm 242:25-36
58. Roux E, Lafleur M, Lataste E, et al. (2003). On the characterization of pH-sensitive liposome/polymer complexes. Biomacromolecules 4: 240-8
59. Roux E, Passirani C, Scheffold S, et al. (2004). Serum-stable and longcirculating, PEGylated, pHsensitive liposomes. J Control Rel 94: 447-51
60. Roux E, Stomp R, Giasson S, et al. (2002b). Steric stabilization of liposomes by pH-responsive N-isopropylacrylamiDe copolymer. J Pharm Sci 91:1795-802
61. Sakaguchi N, Kojima C, Harada A, et al. (2008a). Effect of transferrin as a ligand of pH-sensitive fusogenic liposome-lipoplex hybrid complexes. Bioconjug Chem 19:1588-95
62. Sakaguchi N, Kojima C, Harada A, et al. (2008b). The correlation between fusion capability and transfection activity in hybrid complexes of lipoplexes and pH-sensitive liposomes. Biomaterials 29:4029-36
63. Sakaguchi N, Kojima C, Harada A, Kono K. (2008c). Preparation of pHsensitive poly(glycidol) Derivatives with varying hydrophobicities: their ability to sensitize stable liposomes to pH. Bioconjug Chem 19: 1040-8
64. Sawant RM, Hurley JP, Salmaso S, et al. (2006). SMART drug Delivery systems: double-targeted pH-responsive pharmaceutical nanocarriers. Bioconjug Chem 17:943-9
65. Seddon JM, Cevc G, Marsh D. (1983). Calorimetric studies of the gelfluid (L beta-L alpha) and lamellar-inverted hexagonal (L alpha-HII) phase transitions in dialkyl-and dia-cylophosphatidylethanolamines. Biochemistry 22:1280-9
66. Shi G, Guo W, Stephenson SM, Lee RJ. (2002). Efficient intracellular drug and gene Delivery using folate receptor-targeted pH-sensitive liposomes composed of cationic/anionic lipid combinations. J Control Rel 80:309-19
67. Shigeta K, Kawakami S, Higuchi Y, et al. (2007). Novel histidineconjugated galactosylated cationic liposomes for efficient hepatocyteselective gene transfer in human hepatoma HepG2 cells. J Control Rel 118:262-70
68. Simard P, Leroux JC. (2009). pH-sensitive immunoliposomes specific to the CD33 cell surface antigen of leukemic cells. Int J Pharm 381: 86-96
69. Simard P, Leroux JC. (2010). In vivo evaluation of pH-sensitive polymer-based immunoliposomes targeting the CD33 antigen. Mol Pharm 7:1098-107
70. Simoes S, Moreira JN, Fonseca C, et al. (2004). On the formulation of pH-sensitive liposomes with long circulation times. Adv Drug Del Rev 56:947-65
71. Simoes S, Slepushkin V, Duzgunes N, et al. (2001). On the mechanisms of internalization and intracellular Delivery mediated by pH-sensitive liposomes. Biochim Biophys Acta 1515:23-37
72. Slepushkin VA, Simoes S, Dazin P, et al. (1997). Sterically stabilized pH-sensitive liposomes. Intracellular Delivery of aqueous contents and prolonged circulation in vivo. J Biol Chem 272:2382-8
73. Soares DC, Cardoso VN, De Barros AL, et al. (2012). Antitumoral activity and toxicity of PEG-coated and PEG-folate-coated pHsensitive liposomes containing 159Gd-DTPA-BMA in Ehrlich tumor bearing mice. Eur J Pharm Sci 45:58-64
74. Soenen SJ, Brisson AR, De Cuyper M. (2009). Addressing the problem of cationic lipid-mediated toxicity: the magnetoliposome moDel. Biomaterials 30:3691-701
75. Subbarao NK, Parente RA, Szoka FC, et al. (1987). pH-DepenDent bilayer Destabilization by an amphipathic peptiDe. Biochemistry 26: 2964-72
76. Sudimack JJ, Guo W, Tjarks W, Lee RJ. (2002). A novel pH sensitive liposome formulation containing oleyl alcohol. Biochim Biophys Acta 1564:31-7
77. Tachibana R, Harashima H, Shono M, et al. (1998). Intracellular regulation of macromolecules using pH-sensitive liposomes and nuclear localization signal: qualitative and quantitative evaluation of intracellular trafficking. Biochem Biophys Res Commun 251:538-44
78. Torchilin VP, Zhou F, Huang L. (1993). pH-sensitive liposomes. J Liposome Res 3:201-55
79. Torchilin VP. (1985). Liposomes as targetable drug carriers. CRC Crit Rev Ther Drug Carrier Syst 1:65-115
80. Torres E, Mainini F, Napolitano R, et al. (2011). Improved paramagnetic liposomes for MRI visualization of pH triggered release. J Control Rel 154:196-202
81. Venugopalan P, Jain S, Sankar S, et al. (2002). pH-sensitive liposomes: mechanism of triggered release to drug and gene Delivery prospects. Pharmazie 57:659-71
82. Wang CY, Huang L. (1986). pH-sensitive immunoliposomes mediate target-cell-specific Delivery and controlled expression of a foreign gene in mouse. Proc Natl Acad Sci USA 84:7851-5
83. Wang CY, Huang L. (1987). pH-sensitive immunoliposomes mediate target-cell-specific Delivery and controlled expression of a foreign gene in mouse. Proc Natl Acad Sci USA 84:7851-5
84. Watabe S, Xin KQ, Ihata A, et al. (2001). Protection against influenza virus challenge by topical application of influenza DNA vaccine. Vaccine 19:4434-44
85. Watarai S, Iwase T, Tajima T, et al. (2013). Efficiency of pH-sensitive fusogenic polymer-modified liposomes as a vaccine carrier. Sci World J 2013:1-7
86. Webb MS, Wheeler JJ, Bally MB, Mayer LD. (1995). The cationic lipid stearylamine reduces the permeability of the cationic drugs verapamil and prochlorperazine to lipid bilayers: implications for drug Delivery. Biochim Biophys Acta 1238:147-55
87. Woodle MC, Matthay KK, Newman MS, et al. (1992). Versatility in lipid compositions showing prolonged circulation with sterically stabilized liposomes. Biochim Biophys Acta 1105:193-200
88. Xia G, An Z, Wang Y, et al. (2013). Synthesis of a novel polymeric material folate-poly(2-ethyl-2-oxazoline)-distearoyl phosphatidyl ethanolamine tri-block polymer for dual receptor and pH-sensitive targeting liposome. Chem Pharm Bull (Tokyo) 61: 390-8
89. Yatvin MB, Kreutz W, Horwitz B, Shinitzky M. (1980a). Induced drug release from lipid vesicles in serum by pH-change. Biophys Struct Mech 6:233-4
90. Yatvin MB, Kreutz W, Horwitz BA, Shinitzky M. (1980b). pHsensitive liposomes: possible clinical implications. Science 210: 1253-5
91. Yoshikawa T, Okada N, Oda A, et al. (2008). Development of amphiphilic g-PGA-nanoparticulate cytosolic protein Delivery carrier. Biochem Biophys Res Commun 366:408-13
92. Yu B, Tai HC, Xue W, et al. (2010). Receptor-targeted nanocarriers for therapeutic Delivery to cancer. Mol Membr Biol 27: 286-98
93. Yuba E, Kojima C, Harada A, et al. (2010). pH-sensitive fusogenic polymer-modified liposomes as a carrier of antigenic proteins for activation of cellular immunity. Biomaterials 31:943-51
94. Yuba E, Harada A, Sakanishi Y, et al. (2013). A liposome-based antigen Delivery system using pH-sensitive fusogenic polymers for cancer immunotherapy. Biomaterials 34: 3042-52
95. Zhou F, Huang L. (1995). Delivery of protein antigen to the major histocompatibility complex class I-restricted antigen presentation pathway. J Drug Target 3:91-109
96. Zignani M, Drummond DC, Meyer O. (2000). In vitro characterization of a novel polymeric-based pH-sensitive liposome system. Biochim Biophys Acta 1463:383-94